M. Kulyk & Associates LLC Raises Stock Position in Novo Nordisk A/S $NVO

M. Kulyk & Associates LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 68.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 130,009 shares of the company’s stock after purchasing an additional 52,687 shares during the period. Novo Nordisk A/S makes up approximately 1.5% of M. Kulyk & Associates LLC’s holdings, making the stock its 26th largest position. M. Kulyk & Associates LLC’s holdings in Novo Nordisk A/S were worth $7,214,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Revolve Wealth Partners LLC increased its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the period. Focus Partners Advisor Solutions LLC lifted its stake in shares of Novo Nordisk A/S by 16.3% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 7,318 shares of the company’s stock worth $504,000 after purchasing an additional 1,024 shares during the period. Finally, Leavell Investment Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 18.6% in the second quarter. Leavell Investment Management Inc. now owns 6,250 shares of the company’s stock worth $431,000 after buying an additional 978 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $39.68 on Tuesday. The business’s 50-day simple moving average is $53.56 and its two-hundred day simple moving average is $53.23. Novo Nordisk A/S has a 52 week low of $39.34 and a 52 week high of $93.80. The stock has a market cap of $177.16 billion, a PE ratio of 11.43 and a beta of 0.67. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Wall Street Analyst Weigh In

NVO has been the topic of several recent research reports. HSBC reiterated a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Citigroup began coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $56.07.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Underlying commercial momentum remains: Novo still reports strong Wegovy/Ozempic-era sales and recent quarterly beats that support cash flow and dividends; that steady franchise cushions the setback. Wegovy Growth Beats Expectations
• Neutral Sentiment: Broader market weakness (tariff news, lower futures) amplified NVO’s move today, so part of the decline reflects market context rather than company‑only news. 5 Things to Know Before the Stock Market Opens
• Negative Sentiment: REDEFINE‑4 trial missed its primary non‑inferiority goal: CagriSema produced less weight loss than Lilly’s tirzepatide, raising concerns about Novo’s ability to defend/expand obesity market share. REDEFINE‑4 Trial Results
• Negative Sentiment: Head‑to‑head efficacy gap quantified in market coverage (example: 20.2% average weight loss for CagriSema vs 23.6% for tirzepatide over 84 weeks), a concrete metric investors view as clinically and commercially meaningful. CagriSema vs Tirzepatide Results
• Negative Sentiment: Analyst reaction and legal risk: at least one major shop downgraded NVO to hold and law firms have opened investor investigations alleging possible misstatements, which can increase short‑term selling and volatility. Analyst Downgrade Fraud Investigation Notice
• Negative Sentiment: Market cap and sentiment impact: coverage notes the stock hit multi‑year lows and investors marked off billions in valuation as the market repriced Novo’s obesity growth prospects. Market Reaction / Valuation Impact

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.